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Abstract
Purpose Hyperparathyroidism (HPT) is a common abnormality in patients with end-stage renal disease (ESRD). Since the
introduction of cinacalcet in 2004, a shift from surgery toward predominantly medical treatment has occurred. Surgery is thought
to be associated with more complications than oral medication. The aim of this retrospective study was to evaluate 30-day
outcomes and effectiveness of parathyroidectomy (PTx) in ESRD patients in the Netherlands.
Methods A national database containing data from four academic medical centers in the Netherlands of patients with ESRD-
related HPT, who had undergone PTx and kidney transplantation between 1994 and 2015, was established. Primary endpoints
were 30-day mortality and complication rate. Secondary endpoints were biochemical measurements.
Results We identified 187 HPT patients undergoing PTx, with a median age of 46 years. Median preoperative PTH level was
866 pg/mL (interquartile range [IQR] 407–1547 pg/mL). At 3 months, the median PTH drop from baseline was 93% (IQR, 71–
98%) to a median of 61 pg/mL (IQR, 23–148 pg/mL, p < 0.001). Over the 25-year inclusion period, 13 patients (7.0%) required
re-exploration for persistent or recurrent disease. Thirty-day mortality and complication rate were 0.0% and 7.9% respectively.
Median serum calcium levels improved significantly postoperatively from 2.6 (2.4–2.8) mmol/L to 2.3 (2.1–2.5) mmol/L
(p < 0.001).
Conclusions PTx is a safe and effective procedure in the frail ESRD population. These data show that there should be no
reluctance for surgical intervention and when indicated, nephrologists can safely refer these patients for PTx.
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Introduction
Hyperparathyroidism (HPT), both secondary and tertiary,
is a common complication with a prevalence up to 30–
49% in patients with end-stage renal disease (ESRD) [1,
2]. ESRD-related HPT has been associated with severe
bone disorders, cardiovascular complications, and in-
creased mortality [3–6]. More than a decade ago, the
treatment algorithm of HPT consisted of calcium salts,
vitamin D sterols, and (sub)total parathyroidectomy
(PTx). Since its introduction in 2004, the calcimimetic
agent cinacalcet is being used to treat patients with HPT,
when vitamin D analogs and phosphate binders are insuf-
ficient [7, 8]. The latest update of the Kidney Disease
Improving Global Outcomes (KDIGO) Chronic Kidney
Disease—Mineral and Bone Disorder (CKD-MBD)
guideline recommends cinacalcet even as a first step op-
tion together with vitamin D and phosphate binders in
patients with secondary HPT [8]. Despite the lack of ran-
domized studies that compare cinacalcet with surgical
treatment, the advent of cinacalcet, and in parallel, an
increasing perception of PTx as a high-risk procedure in
this fragile ESRD population has, among other reasons,
led to a shift from surgery toward predominantly medical
treatment [2, 9]. Several studies have shown a reduction
in the number of parathyroidectomies per year since the
introduction of cinacalcet [10, 11]. In a previous study, we
reported that the introduction of cinacalcet is associated
with a 2-year delay of surgery in which patients still had
continuously elevated parathormone (PTH) levels [12].
On the other hand, the inability of cinacalcet to achieve
an efficient and persistent lowering of PTH levels has
been reported in multiple studies [13, 14]. Moreover,
cinacalcet use can be accompanied by serious adverse
events, such as vomiting and diarrhea, which potentially
leads to discontinuation of the drug [14].
In recent years, parathyroid surgery has undergone a
great evolution with the use of minimally invasive tech-
niques and heat-sealing devices [15, 16]. However, surgery
is still thought to be associated with more complications
than oral medication. A nationwide study using United
States Renal Data System (USRD) ESRD data evaluating
the outcome of 4435 hemodialysis patients undergoing PTx
concluded that parathyroid surgery is associated with sig-
nificant morbidity [17]. However, evidence on the periop-
erative risk of PTx performed in specialized, high-volume
centers is poorly documented and the question is whether
the hesitancy for surgical referral also applies to such cen-
ters. Therefore, the aim of this study was to evaluate 30-day
outcomes and effectiveness of PTx in ESRD patients in the
Netherlands. The Dutch Hyperparathyroidism Study Group
was established in 2016 in the Netherlands to address,
among others, this issue.
Material and methods
Study population
A national retrospective database of patients with ESRD-
related HPT who underwent both PTx and kidney transplan-
tation (KTx) in the Netherlands was established, to answer all
distinct research questions. Data from four academic medical
centers (Academic Medical Center [AMC], Erasmus Medical
Center [EMC], Leiden University Medical Center [LUMC],
and University Medical Center Groningen [UMCG]) of pa-
tients with ESRD-related HPT undergoing PTx between 1994
and 2015 were extracted. Databases were cross-checked be-
tween participating centers. The study population included all
patients diagnosed with ESRD in the aforementioned medical
centers, aged ≥ 18 years who underwent PTx and KTx.
Secondary HPT was defined as HPT in patients receiving
hemodialysis and tertiary HPT as HPT in patients who
underwent KTx. Approval from the medical ethical commit-
tee boards of all centers was retrieved. Data was collected and
stored in concordance with the Declaration of Helsinki.
Patient characteristics and primary and secondary
endpoints
Patient characteristics were derived from each hospital’s elec-
tronic medical record system. Collected data consisted of age,
sex, primary ESRD cause, time on dialysis, history of KTx,
preoperative American Society of Anesthesiologists (ASA)
physical status classification, type of PTx, medication related
to calcium-phosphate metabolism, postoperative complica-
tions (including recurrent laryngeal nerve damage, wound
problems, hospital-acquired pneumonia, and intensive care
unit admission), and mortality. Patients who presented with
hoarseness pre- or postoperatively were offered laryngoscopy
performed by a qualified ear nose and throat specialist to eval-
uate the vocal cords and intactness of the recurrent laryngeal
nerve. The primary outcome was 30-day mortality and com-
plication rate (including the aforementioned complications).
Secondary endpoints were biochemical measurements, in-
cluding pre- and postoperative PTH levels, calcium, phos-
phate, albumin, alkaline phosphatase (ALP), and creatinine.
Furthermore, reoperation rate and time until reoperation were
recorded. Serum calcium levels were adjusted for albumin
using the following equation: adjusted total calcium
(mmol/L) = measured calcium (mmol/L) + (0.025 × (40 − [al-
bumin (g/L)]). Reference interval was 2.20–2.60 mmol/L. To
calculate the proportion of patients that were hypocalcaemic
during follow-up, serum-adjusted calcium concentrations
were categorized into three groups: low calcium (<
2.20 mmol/L), adequate calcium (2.20–2.60 mmol/L), and
high calcium (> 2.6 mmol/L). Postoperative hypocalcaemia
rates were compared between patients who underwent
Langenbecks Arch Surg
subtotal PTx and total PTx with AT. The reference interval for
serum phosphate levels was 0.7–1.5 mmol/L. In a subanalysis,
we compared all biochemical levels between patients with
secondary HPT and those with tertiary HPT.
Surgical protocol
Patients were referred for surgical treatment in case of disease
refractory to pharmacological treatment (including vitamin D
analogs, phosphate binders, and calcimimetics). Other indica-
tions for surgical referral included intolerance to or noncompli-
ance of cinacalcet, severe disease with highly elevated serum
PTH and calcium levels, symptomatic disease, patient’s prefer-
ence, and persistent hypercalcemia after KTx. All patients
underwent a subtotal PTx or total PTx + autotransplantation
(AT). In subtotal PTx, 3.5 of the four glands were resected.
Total PTx +ATcomprised of the resection of all four parathyroid
glands whereafter half of the most normal-appearing parathyroid
gland was minced and then autotransplanted in the
sternocleidomastoid muscle or into subcutaneous pockets of the
forearm. During PTx, intraoperative PTH measurements were
available in all centers. When intraoperative PTH measurement
was used, serum concentration PTH was determined before re-
section of the parathyroid glands, and 5, 10, 15, and 20 min after
resection. In general, an intraoperative drop of PTH of ≥ 85%
was considered to be sufficient for a successful operation [18]. In
case of an inadequate PTH drop, surgeons looked for extra or
ectopic parathyroid glands.
In each medical center, pre- and postoperative calcium
management was handled according to the local protocol
and included both oral and, if necessary, intravenous calcium
supplementation.
Statistical analysis
Statistics were performed using SPSS Statistics version 24.0
(IBM Corporation, Armonk, NY, USA.). Continuous variables
are described as mean ± SD (normal distribution) or median with
interquartile range (IQR) in case of skewed distribution.
Distribution was assessed with the Shapiro-Wilk normality test.
Categorical variables are expressed as number (n) and percentage
(%). Subsequent laboratory values were compared using the
paired sample t test or related sample Wilcoxon signed-rank test.
p values ≤ 0.05 were considered statistically significant.
Results
Patient characteristics
A total of 187 patients were included in this study. Baseline
characteristics of the included patients are listed in Table 1.
Median age was 46 years (IQR, 33–57), and 50.3% were
female. Of all patients, 58.3% underwent total PTx +
autotransplantation (AT) whereas 41.7% underwent subtotal
PTx. Sixty-nine percent of patients were classified ASA III or
higher. Before surgery, 70.7% of patients were using phos-
phate binders, 61.9% calcium supplements, and 77.1% vita-
min D analogs. Eighteen percent used calcimimetics. Of all
patients, 103 (55%) underwent a KTx after PTx; the remain-
ing 45% underwent a KTx prior to PTx. Median time until
KTx was 22 (IQR, 10–38) months after PTx. The proportion
of secondary (patients on dialysis) and tertiary (patients with a
kidney transplant) HPT patients and type of PTx per center are
shown in Fig. 1.
Table 1 Characteristics
of ESRD patients at the
time of PTx
N = 187
Age, y (IQR) 46 (33–57)
Female sex, n (%) 94 (50.3)
Diabetes mellitus, n (%)
DM type 1 7 (3.7)
DM type 2 18 (9.6)
Type renal replacement therapy, n (%)
None 13 (7.0)
Hemodialysis 49 (26.2)
Peritoneal dialysis 41 (21.9)
Kidney transplantation 84 (44.9)
Type of PTx, n (%)
Total PTx + AT 109 (58.3)
Subtotal PTx 78 (41.7)
ASA classification, n (%)
ASA II 58 (31.0)
ASA III 126 (67.4)
ASA IV 3 (1.6)
KTx, kidney transplantation; DM, diabetes
mellitus; PTx, parathyroidectomy; AT,
autotransplantation; ASA, American
Society of Anesthesiologists
Fig. 1 Type of HPT and PTx per medical center
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Preoperative and short-term laboratory values
Preoperative biochemical levels are shown in Table 2, sepa-
rated for patients with secondary hyperparathyroidism (e.g.,
those who did not have a KTx in medical history) and patients
with tertiary hyperparathyroidism (e.g., those who underwent
KTx prior to PTx). All preoperative laboratory values were
significantly different between the two groups. Median preop-
erative PTH level of all patients was 866 pg/mL.
Intraoperative PTH measurements were available in 120 pa-
tients. During PTx, PTH levels dropped significantly during
surgery with a median of 86% (IQR, 72–95%, p < 0.001).
Median drop of PTH of all patients after 3 months was 93%
(IQR, 71–98%) from 866 (407–1447) pg/mL to 61 (23–148)
pg/mL. Postoperatively, PTH levels were not significantly dif-
ferent for patients with secondary HPT compared to tertiary
HPT patients.
Median-adjusted calcium levels improved significantly af-
ter PTx from a median of 2.6 (2.4–2.8) mmol/L to 2.3 (2.1–
2.5) mmol/L (p < 0.001) and did not significantly differ
between secondary HPT patients and tertiary HPT patients.
Preoperative phosphate levels were high in patients with
secondary HPTand low but within the range of normal (0.81–
1.45 mmol/L) in patients with tertiary HPT (Table 2). Of all
patients, 56.7% of patients had serum phosphate concentra-
tions above the upper limit of normal, mainly reflecting sec-
ondary HPT patients. Median phosphate levels did not change
significantly after surgery (p = 0.1); at 3 months of follow-up,
43.9% of patients had serum phosphate levels above the upper
limit of normal. Postoperative phosphate levels were signifi-
cantly different at 3, 6, and 12 months between secondary and
tertiary HPT levels, but all within the reference range.
Long-term laboratory values
Postoperative serum PTH levels remained low and overall did
not increase during the 5-year follow-up compared to the
levels of 3 months postoperatively (Fig. 2 and Table 3). At
3 months, 38.7% were hypocalcaemic (adjusted serum calci-
um levels < 2.20 mmol/l). Fourteen patients (9.9%) still had
calcium levels above the upper limit of normal. The propor-
tion of patients within the reference range at 5 years
postoperatively was 68.3%. Median corrected calcium levels
remained within the reference interval (2.20–2.60 mmol/L)
and did not increase significantly during follow-up. All post-
operative laboratory values are displayed in Table 3.
Postoperative complications
Postoperative complications are listed in Table 4. Of all pa-
tients who underwent PTx, the 30-day mortality rate was zero.
Four patients experienced temporary hoarseness after surgery,
which was objectified by laryngoscopy. Clinically, all four
patients had full recovery of their voice within 1 year. In
48.5% of the patients, hypocalcaemia was reported during
hospital admission. Intensive care admission to treat
hypocalcaemia was required in 2.4% of the patients. Three
months after PTx, 37.4% of patients were still using calcium
supplements. Calcium supplements were required in 32.6% of
patients at 1 year after surgery. No difference in postoperative
hypocalcaemia rates was found between patients who
underwent subtotal PTx and those who underwent total PTx
with AT at any time point after PTx.
Reoperation rates
Of all 187 patients, 13 patients (7.0%) underwent a reopera-
tion for persistent or recurrent disease. Median time until re-
exploration was 6 months (IQR, 1–24 months). One patient
(0.5%) underwent re-exploration during the initial admission
for a postsurgical hemorrhage.
Discussion
End-stage renal disease (ESRD) is often complicated by the
development of hyperparathyroidism (HPT); more than 80%
of patients with a glomerular filtration rate (GFR) below
20 mL/min develop serum PTH levels exceeding the upper
limit of normal [19]. Historically, patients were referred for
parathyroidectomy (PTx) when vitamin D analogs and phos-
phate binders were no longer sufficient to control calcium-
phosphate homeostasis [7]. However, since its introduction
in 2004, cinacalcet has become the second step in the
Table 2 Laboratory values preoperatively
Total Secondary hyperparathyroidism
(PTx before KTx)
Tertiary hyperparathyroidism
(PTx after KTx)
p value
PTH, pg/mL 866 (407–1547) 1143 (702–1776) 476 (243–1162) < 0.01
Adjusted calcium, mmol/L 2.6 (2.4–2.8) 2.5 (2.3–2.7) 2.7 (2.5–2.9) < 0.01
Phosphate, mmol/L 1.4 (0.9–1.9) 1.77 (1.5–2.1) 0.90 (0.7–1.35) < 0.01
Creatinine, μmol/L 477 (137–927) 828 (523–1018) 141 (112–426) < 0.01
PTx, parathyroidectomy; KTX, kidney transplantation; PTH, parathyroid hormone
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treatment of HPT and surgery rates decreased without strong
evidence to support this practice [8, 20]. This multicenter ret-
rospective study reports surgical outcomes of parathyroidec-
tomy (PTx) in patients with ESRD-related HPT. Our results
indicate that PTx is associated with no 30-day mortality and
very low 30-day morbidity rates. Three months after surgery,
serum PTH levels dropped significantly to a median of 61 pg/
mL (93% drop) and remained low during 5 years of follow-up.
Our results are supported by multiple previous studies that
reported high success rates of PTx [21, 22]. Previously docu-
mented PTH drop rates ranged from 89 to 98% [23–25]. Since
the introduction of calcimimetics in 2004 however, PTx is
thought to be associated with more complications than oral
medication, and a paradigm shift in referring patients for sur-
gery occurred [12]. On top of that, as mentioned before, au-
thors of a nationwide study in the USA reported high compli-
cation rates following parathyroid surgery [17]. The authors
observed a rehospitalization rate due to complications of
23.8% and almost 30% of these patients required ICU admis-
sion. Indications for ICU admission were not elaborated in the
article. These findings are in sharp contrast with our results.
This variance can be explained by the inclusion of Medicare
insurance centers in this American study, which may have led
to the inclusion of patients in low-volume, less specialized
centers. The discrepancy between these results emphasizes
the need to refer these patients to experienced medical centers
dedicated to (para)thyroid surgery. In the Netherlands, sur-
geons, endocrinologists, and nephrologists work in close col-
laboration to improve patient health care; patients are
elaborated preoperatively in a multidisciplinary meeting, sur-
geons are required to perform over 20 (para)thyroid surgeries
a year, and after PTx, the patient is monitored by both their
surgeon as well as their nephrologist/endocrinologist. A min-
imum number of required (para)thyroid procedures per sur-
geon ensure quality across medical centers. More in concor-
dance with our results, multiple other studies also reported low
complication rates after PTx [26, 27]. In the literature, HPT
recurrence rates requiring reoperation ranged between 5 and
30%. Those results are in line with our findings (7%) [24, 28].
Hypocalcaemia is a frequently mentioned consequence of
PTx in patients with secondary or tertiary hyperparathyroid-
ism [29]. The finding that a substantial proportion of patients
are temporarily hypocalcaemic after PTx emphasizes the need
for strict observation and protocol in collaboration with a ne-
phrologist or endocrinologist.
In the treatment of secondary and tertiary HPT, both phar-
macological and surgical management are well-recognized
options. Since its introduction of calcimimetics in 2004,
cinacalcet gained a dominant position in the treatment algo-
rithm and prescription patterns increased significantly over the
years [19]. However, in 2012, the EVOLVE Trial
Investigators published their results of a randomized con-
trolled trial evaluating the effect of cinacalcet on the risk of
death or cardiovascular events compared to placebo in 3883
dialysis patients [14]. The authors concluded that cinacalcet
did improve serum PTH and calcium levels, but it did not
significantly reduce the risk of death or cardiovascular events
(cinacalcet vs. placebo, relative hazard 0.93, 95% confidence
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Fig. 2 Parathormone (PTH)
levels over time
Table 3 Postoperative laboratory values
3 months 6 months 1 year 3 years 5 years
PTH, pg/mL 61 (23–148) 80 (23–195) 58 (22–143) 106 (38–181) 85 (35–230)
Adjusted calcium, mmol/L 2.3 (2.1–2.5) 2.3 (2.1–2.4) 2.3 (2.1–2.4) 2.3 (2.2–2.4) 2.3 (2.2–2.4)
Phosphate, mmol/L 1.2 (0.9–1.6) 1.3 (0.9–1.7) 1.2 (0.9–1.7) 1.1 (0.9–1.4) 1.0 (0.9–1.3)
Creatinine, μmol/L 545 (148–1018) 476 (150–995) 271 (142–1001) 183 (123–601) 167 (116–224)
PTH, parathormone
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interval 0.85–1.02; p = 0.11). Of note, a significant difference
of 1 year in age between the two groups, a high drug discon-
tinuation rate, and a high cross-over between the two treat-
ment arms may have led to the minimal impact of cinacalcet
on the primary composite endpoint. Moreover, the use of
cinacalcet is often accompanied with a range of (gastro-
intestinal) adverse effects, leading to discontinuation or non-
compliance [13, 14]. Almost half of the patients on cinacalcet
participating in the EVOLVE trial reported adverse events
compared to 19% of the placebo group.
These findings, together with the results of an increasing
number of articles reporting on the limited impact of
cinacalcet on PTH, its costs, side effects, and minimal bene-
ficial impact on QoL should be taken into account when new
guidelines are established in the future [13, 14, 30, 31]. A
decisive randomized controlled study comparing pharmaceu-
tical treatment with PTx head-to-head is still not available.
This RCT is needed before the optimal treatment for these
patients can be determined.
This study has several limitations that need to be addressed.
First, the retrospective nature of this analysis could have led to
selection bias in our recorded data and missing data was some-
times inevitable. For instance, patients were only included if
they underwent both a PTx and KTx. Patients who underwent
KTx before PTx as well as patients who underwent KTx after
PTx were included. This may also have led to selection bias
since patients who were not eligible for KTx were not includ-
ed. Our conclusions of the safety of PTx might only be appli-
cable in patients who are found to be also eligible for KTx.
Secondly, this study population is a heterogeneous patient
group with multiple comorbidities [32].
More than half of our patients underwent KTx after PTx
after a median time of 22 months. This event influenced the
biochemical results during long-term follow-up. One of the
strengths of this multicenter study is that data from four aca-
demic hospitals in the Netherlands were included. Our find-
ings can be generalized to other (academic) medical centers
with a similar type of health care and quality standards.
In patients with secondary HPT, KTx leads to an amelio-
ration of the disturbance of the calcium-phosphate homeosta-
sis in more than half of the patients [33]. Therefore, if kidney
transplantation is not expected in the near future, and in case
of severe disease with debilitating symptoms, PTx is a safe
and effective option. In patients with tertiary hyperparathy-
roidism, kidney transplantation apparently did not improve
calcium-phosphate homeostasis and PTH levels continue to
rise. In these patients, PTx is considered the only definite
option to treat the persistent hyperparathyroidism.
In conclusion, our results indicate that PTx is a very safe
and effective procedure in patients with ESRD-related HPT, a
patient population with extensive comorbidities. Although an
invasive procedure requiring general anesthesia, recovery is
fast and without major complications. Our patients were op-
erated in high-volume and high-experienced medical centers,
which may have contributed to high success rates.
Nevertheless, these findings implicate that there should be
no reluctance in referring these patients for PTx, when indi-
cated, despite their comorbidity and high ASA classification.
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